Financial Survey: Janux Therapeutics (NASDAQ:JANX) vs. I-Mab (NASDAQ:NBP)

I-Mab (NASDAQ:NBP) and Janux Therapeutics (NASDAQ:JANX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Institutional and Insider Ownership

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

I-Mab has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500.

Earnings & Valuation

This table compares I-Mab and Janux Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89 million	39.66	-$46.27 million	($0.36)	-3.69
Janux Therapeutics	$10.00 million	104.30	-$113.62 million	($1.64)	-10.40

I-Mab has higher earnings, but lower revenue than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares I-Mab and Janux Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Janux Therapeutics	N/A	-11.89%	-11.13%

Analyst Ratings

This is a breakdown of current recommendations for I-Mab and Janux Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1	0	1	0	2.00
Janux Therapeutics	2	2	10	1	2.67

I-Mab presently has a consensus target price of $9.00, indicating a potential upside of 576.69%. Janux Therapeutics has a consensus target price of $36.46, indicating a potential upside of 113.73%. Given I-Mab’s higher possible upside, equities analysts clearly believe I-Mab is more favorable than Janux Therapeutics.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.

About Janux Therapeutics

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.